Cell Signaling Technology Logo
1% for the planet logo
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

SLPI (F6Z7H) Rabbit mAb #17012

Filter:
  • WB

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 14
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    SLPI (F6Z7H) Rabbit mAb recognizes endogenous levels of total SLPI protein. This antibody detects an 85 kDa protein of unknown identity in some cell lines.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Phe30 of human SLPI protein.

    Background

    Secretory leukocyte protease inhibitor (SLPI), also known as antileukoproteinase, is a small protein expressed primarily at mucosal surfaces (1), where it helps to protect against inflammation by inhibiting proteases, including elastase, chymotrypsin, and cathepsin G (2,3). SLPI also exerts antimicrobial activity against various Gram-positive and Gram-negative bacteria, some fungi and viruses, and suppresses the production of pro-inflammatory cytokines through NF-kB inhibition (1,4). SLPI has recently been shown to be upregulated in cancer-associated fibroblasts, and extracellular vesicle-encapsulated SLPI levels were reported to be correlated with tumor stage in ovarian cancer patients (5). Higher SLPI expression levels are also correlated with poorer prognosis in other cancer types, including colorectal and breast cancer (6,7). SLPI is essential for normal granulocytic differentiation and may be of therapeutic interest for congenital neutropenia patients (8).
    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.